Sugi Predict

Sugi Predict / Compounds / SCHEMBL2245357

SCHEMBL2245357

SCHEMBL2245357

CC(C)(C)OC(=O)N1CCC(Nc2ncccc2[N+](=O)[O-])CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 7/20 0.51
▸ ALDH1A1 P00352 3/20 0.50
▸ MAPT P10636 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ POLB P06746 1/20 0.47
▸ BTK Q06187 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CCNA2 P20248 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ NOS2 P35228 1/20 0.45
▸ MET P08581 1/20 0.45
▸ USP30 Q70CQ3 1/20 0.44
▸ CNR1 P21554 2/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ NSD2 O96028 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30594366 1.00 GPR119 (0.51) GPR119ALDH1A1MAPTNPC1MAPK1
SCHEMBL28876430 0.94 BTK (0.50) GPR119ALDH1A1POLBBTKUSP30
SCHEMBL12126177 0.94 BTK (0.50) GPR119ALDH1A1POLBBTKUSP30
SCHEMBL31170913 0.94 BTK (0.50) GPR119ALDH1A1POLBBTKUSP30
SCHEMBL30085312 0.94 BTK (0.50) GPR119ALDH1A1POLBBTKUSP30
SCHEMBL29124390 0.94 BTK (0.50) GPR119ALDH1A1POLBBTKUSP30
SCHEMBL21811143 0.89 PRKCQ (0.44) GPR119ALDH1A1MAPTNPC1MAPK1
SCHEMBL31170936 0.89 PRKCQ (0.44) GPR119ALDH1A1MAPTNPC1MAPK1
SCHEMBL13506830 0.86 NOS2 (0.62) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL29241131 0.84 POLB (0.39) GPR119ALDH1A1MAPTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425504-A1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) 2024-12-26 — — US disclosed
EP-3808747-B1 IMIDAZOPYRIDINONE COMPOUND KISSEI PHARMACEUTICAL (JP) 2024-12-18 — — EP disclosed
US-12077531-B2 Imidazopyridinone compound KISSEI PHARMACEUTICAL CO., LTD. (JP) 2024-09-03 — — US disclosed
US-20240067645-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF LG CHEM, LTD. (KR) 2024-02-29 — — US disclosed
US-20240067645-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF LG CHEM, LTD. (KR) 2024-02-29 — — US disclosed
WO-2023229378-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF 주식회사 엘지화학 2023-11-30 — — WO disclosed
WO-2023229380-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF 주식회사 엘지화학 2023-11-30 — — WO disclosed
CN-112689637-B Imidazopyridone compounds 橘生药品工业株式会社 2023-11-10 — — CN disclosed
EP-4249489-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF Lg Chem, Ltd. (KR) 2023-09-27 — — EP disclosed
CN-116615199-A Heterocyclic compounds as diacylglycerol kinase inhibitors and uses thereof 株式会社LG化学 2023-08-18 — — CN disclosed
US-20130225552-A1 HETEROBICYCLIC COMPOUNDS AMGEN INC. (US) 2013-08-29 — — US disclosed
US-20130225552-A1 HETEROBICYCLIC COMPOUNDS AMGEN INC. (US) 2013-08-29 — — US disclosed
US-8058292-B2 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. (US) 2011-11-15 — — US disclosed
US-20110190336-A1 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2011-08-04 — — US disclosed
US-20110190336-A1 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2011-08-04 — — US disclosed
US-20110190336-A1 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2011-08-04 — — US disclosed
US-20100256111-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (US) 2010-10-07 — — US disclosed
US-7767699-B2 Therapeutic agents useful for treating pain PURDUE PHARMA, L.P. (US) 2010-08-03 — — US disclosed
WO-2010045276-A2 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2010-04-22 — — WO disclosed
WO-2010045276-A2 AZABENZIMIDAZOLONES CARA THERAPEUTICS, INC. (US) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077531-B2 Imidazopyridinone compound EGLN3, DHPS, EGLN2 GPR119 1360/4885ALDH1A1 84/4885MAPT 4146/4885
US-20130225552-A1 HETEROBICYCLIC COMPOUNDS PDE10A, PDE1B, PDE9A GPR119 8/4885ALDH1A1 1910/4885MAPT 136/4885
US-20110190336-A1 AZABENZIMIDAZOLONES PTGER1, PTGDR, PTGER2 GPR119 569/4885ALDH1A1 1323/4885MAPT 4726/4885
US-20240425504-A1 IMIDAZOPYRIDINONE COMPOUND EGLN3, DHPS, EGLN2 GPR119 1360/4885ALDH1A1 84/4885MAPT 4146/4885
US-20240067645-A1 HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF DGKA, DGKB, DGKK GPR119 655/4885ALDH1A1 2241/4885MAPT 4016/4885
US-20100256111-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN CHRNA10, ACHE, SNCA GPR119 76/4885ALDH1A1 453/4885MAPT 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.